|

March
2004
Acting
Director of U.S. AIDS Policy Speaks to NORA
On
Monday, March, 8, the National Organizations Responding to AIDS
(NORA), for which AIDS Action serves as convener, held its monthly
meeting. The featured guest speaker of the meeting was Christopher
Bates, the Acting Director of the Office of National AIDS Policy
(ONAP) at the Department of Health and Human Services (DHHS).
He gave his perspective of the state of federal HIV policy and
funding and then fielded questions from attending NORA members.
According
to Mr. Bates, his perspective can best be described as realistic
but cautiously optimistic. He opened by commenting on the “interesting
times” in which we are living and characterized these times by
discussing the limited resources we are facing as a country. “Many
of our dollars are leaving the U.S. to address priorities abroad
and we all [as advocates] ace fierce competition for the funding
that remains.” We have witnessed this reality most recently with
the issuance of the Ryan White CARE Act Title I awards, he pointed
out. Title I grants pay for HIV care and treatment in 51 eligible
metropolitan areas (EMAs), or those areas with a population of
at least 500,000 that reported 2,000 or more AIDS cases during
the previous five years. Many EMAs were award grants that were
lower than what they had received the previous year. The funding
decreases overall amounted to more than $4 million.
The
HHS official went on to discuss his concentration on the reauthorization
of the Ryan White CARE Act in 2005. Although he is focused on
it, he has been met with several disappointments which make that
focus difficult. First, HHS was disappointed in the outcome of
the Institute of Medicine (IOM) report—commissioned by the Health
Resources and Services Administration (HRSA) and released late
last year—which investigated the formulas for grant awards issued
through the CARE Act. The report concluded that basing award formulas
on HIV reporting rather than cumulative AIDS case reporting would
not make a significant difference in funding distribution. Mr.
Bates also made it clear that the community (i.e., national organizations
and community activists) is of vital importance to the reauthorization
process. In fact, he said that he has been waiting to hear from
the community on some concrete proposals for reauthorization but
he has not yet heard from a unified community voice which, he
cautioned, makes it more difficult for him to help the community
achieve its goals.
Mr.
Bates also opined that even great opportunities in the response
to HIV can bring with them great challenges. Illustrating his
point, he cited the unrolling of the Center for Disease Control
and Prevention’s (CDC) Advancing HIV Prevention (AHP) Initiative,
which is concentrating HIV prevention efforts in a few strategic
areas: integrating HIV testing into all primary medical care;
prevention programs directed at HIV positive persons and HIV negative
persons who are at high risk for HIV; aggressive voluntary HIV
testing for all pregnant women; and the increased use of the rapid
HIV test. These tactics are expected to identify more HIV positive
persons than ever before (as well as prevent new infections from
occurring). But while it is expected that the number of people
who will need such services will increase, federal funding levels
are decreasing. Mr. Bates acknowledged that the HIV community
is going to have to do more with less. On a more positive note,
however, he claimed that these challenges can be translated into
powerful messages to deliver to Congress when advocating for increased
federal spending on HIV programs. Indeed, he even reminded meeting
attendees that there is still time to push for budget increases
for fiscal year (FY) 2005, and we have a lot of “ammunition” for
effective arguments for such increases.
Mr.
Bates concluded his prepared comments by affirming his dedication
to the domestic HIV epidemic. He reminded everyone that, to see
the devastation caused by HIV, you don’t have to travel to another
country; you can simply travel to some parts of Washington, DC
to see the grave impact of HIV on communities.
During
the question-and-answer period with NORA members, Mr. Bates, prompted
by questions, raised several significant points.
- He
affirmed the significant investment that the U.S. makes annually
for domestic HIV care, treatment, and prevention—totaling $16.7
billion.
-
He discussed the unforeseen problems that many jurisdictions
are having in the implementation of the rapid test—specifically
around cost. The test costs $8.00 to $9.00 as opposed to the
$3.50 to $4.00 for the standard test. Budget are being strained
further by the cost of training people who can then go out and
train others on administering HIV rapid tests.
-
He encouraged communities to come up with contingency plans
for connecting clients to care services while they are waiting
for funding to adequately address the increasing number of people
in need of such services. At the very least, service providers
need to keep track of the people who are not able to get into
care immediately.
-
He shared that he thinks the big increase in HIV positive clients
is going to come with the second year (i.e., next year) of the
implementation of the CDC’s Advancing HIV Prevention initiative.
-
Lastly, he suggested that meeting participants to think of the
“hard-to-reach” clients as “hardly reached” instead. This re-characterization
puts the onus on all HIV service providers and advocates for
HIV positive people to do their jobs better.
|